Highlights Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Market Closed - Nasdaq Other stock markets 21:30:00 16/05/2024 BST			5-day change	1st Jan Change
3.63 ^USD	-0.55%		-12.53%	-69.94%

05-15	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-18	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy	02-22	CI
Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	01-02	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study	01/08/23	CI
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	27/07/23	CI
Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol	25/07/23	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
North American Morning Briefing : China Data Helps Support Sentiment	18/04/23	DJ
Avenue Therapeutics, Inc. Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of Iv Tramadol	17/04/23	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
North American Morning Briefing : Stock Futures Dip as Higher Rate Fears Persist	09/03/23	DJ
Avenue Therapeutics Signs License Agreement to Develop, Commercialize Kennedy's Disease Treatment	02/03/23	MT
Avenue Therapeutics, Inc. Enters into A License Agreement with Annji Pharmaceutical Co. Ltd	02/03/23	CI
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Earnings Flash (ATXI) AVENUE THERAPEUTICS Reports Q3 Loss $-0.45	10/11/22	MT
Avenue Therapeutics, Inc. acquired Baergic Bio, Inc from Fortress Biotech, Inc.	07/11/22	CI
Health Care Up on Inflationary Bias -- Health Care Roundup	05/10/22	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Highlights

Filters